Improving Patient Lives with Single Cell Precision
HiFiBiO Therapeutics, a clinical-stage global biotech, is pioneering a unique high-resolution translational platform (DIS®) to enhance the probability of success for immunotherapies
HiFiBiO Therapeutics, a clinical-stage global biotech, is pioneering a unique high-resolution translational platform (DIS®) to enhance the probability of success for immunotherapies
Our Science
We apply single cell science at every stage of drug development from target discovery to predictive biomarkers, enabling rapid advancement of new therapeutics into the clinic.
Read moreOur SOAR Values
We unite under a shared mission to SOAR to new heights in science and healthcare.
Read moreCAMBRIDGE, MA – March 21, 2024 – HiFiBiO Therapeutics, a leading clinical stage global biotechnology company committed to advancing patient outcomes through single-cell precision, announced today its participation in the AACR 2024 meeting, scheduled to take place April 5-10, 2024, in San Diego, CA. On Tuesday, April 9th, Dr. Jack Russella-Pollard will present an … Continued
CAMBRIDGE, MA., – January 7, 2024 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with Nasdaq Live from MarketSite to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies by gaining an unprecedented understanding of immune dysregulation at the single cell level. HiFiBiO’s unique high-resolution translational DIS® platform enhances the probability … Continued
Paris, France, and Cambridge, MA, December 11, 2023 – HiFiBiO Therapeutics, a leading clinical stage global biotech company dedicated to advancing patient outcomes through single-cell precision, proudly announces its strategic collaboration with clinical institutions and life science companies in the formation of a groundbreaking consortium under the France 2030 Initiative. This visionary project, named REMISSION … Continued
CAMBRIDGE, MA – March 21, 2024 – HiFiBiO Therapeutics, a leading clinical stage global biotechnology company committed to advancing patient outcomes through single-cell precision, announced today its participation in the AACR 2024 meeting, scheduled to take place April 5-10, 2024, in San Diego, CA. On Tuesday, April 9th, Dr. Jack Russella-Pollard will present an … Continued
HiFiBiO Therapeutics single-cell focused platform identifies translationally relevant targets, enables rapid drug development, and matches treatments to patients for better clinical outcomes